Inhibikase Therapeutics Inc
Research Inhibikase Therapeutics Inc (IKT) on Bullrun: market cap USD 243.60M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIKT
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 243.60M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 19.59M
- Free cash flow-USD 12.44M
Valuation Snapshot
latest market cap is USD 243.60M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 48.26M | -USD 27.80M | n/a | -0.49 | USD 178.80M | USD 0 | USD 172.90M |
| FY2024 | USD 0 | -USD 27.52M | -USD 19.15M | n/a | -1.16 | USD 97.50M | USD 110.52K | USD 94.87M |
| FY2023 | USD 260.50K | -USD 19.03M | -USD 18.10M | n/a | -3.16 | USD 9.20M | USD 381.78K | USD 10.98M |
| FY2022 | USD 123.44K | -USD 18.05M | -USD 17.59M | n/a | -4.28 | USD 7.19M | USD 351.29K | USD 21.04M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 243.60M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 269.97M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 225.43M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 7.84M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 12.61M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 36.98M | n/a | n/a | n/a |
About Inhibikase Therapeutics Inc
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Inhibikase Therapeutics Inc's market cap?
Inhibikase Therapeutics Inc's market capitalization is USD 243.60M.
What does Inhibikase Therapeutics Inc do?
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance.